About the event

Held over a weekend, the event is structured around a series of exhibitions, workshops, and panel discussions. The exhibitions showcase a curated selection of photographs that tell compelling stories from various corners of the globe, each image accompanied by detailed narratives that provide context and deeper insight into the historical significance of the scenes depicted. These photographs are drawn from the archives of renowned photographers, as well as emerging talents, ensuring a blend of both classical and contemporary perspectives.

Cliff Palace, Colorado
Investor’s Delight: ORIC Pharmaceuticals Inc (ORIC) Closes Weak at 11.62, Down -1.44 – DwinneX

Investor’s Delight: ORIC Pharmaceuticals Inc (ORIC) Closes Weak at 11.62, Down -1.44

Abby Carey

Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.

The closing price of ORIC Pharmaceuticals Inc (NASDAQ: ORIC) was $11.62 for the day, down -1.44% from the previous closing price of $11.79. In other words, the price has decreased by -$1.44 from its previous closing price. On the day, 1.09 million shares were traded. ORIC stock price reached its highest trading level at $12.29 during the session, while it also had its lowest trading level at $11.47.

Ratios:

Our analysis of ORIC’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 14.65 and its Current Ratio is at 14.65. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.

Upgrades & Downgrades

In the most recent recommendation for this company, Evercore ISI on November 20, 2025, initiated with a Outperform rating and assigned the stock a target price of $25.

Insider Transactions:

Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Oct 06 ’25 when Piscitelli Dominic sold 11,000 shares for $14.52 per share. The transaction valued at 159,719 led to the insider holds 48,317 shares of the business.

Chacko Jacob sold 37,461 shares of ORIC for $461,520 on Oct 06 ’25. The PRESIDENT AND CEO now owns 531,419 shares after completing the transaction at $12.32 per share. On Oct 06 ’25, another insider, Dominic Piscitelli, who serves as the Officer of the company, bought 50,000 shares for $14.50 each.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ORIC now has a Market Capitalization of 1131663360 and an Enterprise Value of 851918400.

Stock Price History:

The Beta on a monthly basis for ORIC is 1.33, which has changed by 0.18254769 over the last 52 weeks, in comparison to a change of 0.1177547 over the same period for the S&P500. Over the past 52 weeks, ORIC has reached a high of $14.93, while it has fallen to a 52-week low of $3.90. The 50-Day Moving Average of the stock is -5.76%, while the 200-Day Moving Average is calculated to be 25.13%.

Shares Statistics:

ORIC traded an average of 1.32M shares per day over the past three months and 1228330 shares per day over the past ten days. A total of 97.28M shares are outstanding, with a floating share count of 54.16M. Insiders hold about 44.39% of the company’s shares, while institutions hold 68.89% stake in the company. Shares short for ORIC as of 1763078400 were 16253539 with a Short Ratio of 11.75, compared to 1760486400 on 13020257. Therefore, it implies a Short% of Shares Outstanding of 16253539 and a Short% of Float of 16.900000000000002.

Earnings Estimates

The stock of ORIC Pharmaceuticals Inc (ORIC) is currently being evaluated by 12.0 analysts who are actively contributing to its market rating.The consensus estimate for the next quarter is -$0.41, with high estimates of -$0.3 and low estimates of -$0.54.

Analysts are recommending an EPS of between -$1.48 and -$2.41 for the fiscal current year, implying an average EPS of -$1.66. EPS for the following year is -$1.63, with 12.0 analysts recommending between -$1.22 and -$2.54.

DwinneX
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.